Yifan Pharmaceutical Co., Ltd. (SHE:002019)
China flag China · Delayed Price · Currency is CNY
9.31
+0.11 (1.20%)
Sep 14, 2026, 3:04 PM CST

Yifan Pharmaceutical Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Equivalents
884.25732.97889.39698.371,1441,336
Trading Asset Securities
---75.0195.5-
Cash & Short-Term Investments
884.25732.97889.39773.381,2391,336
Cash Growth
12.51%-17.59%15.00%-37.59%-7.25%-2.51%
Accounts Receivable
1,4681,5711,5071,2091,2581,145
Other Receivables
94.3392.49105.5780.69112.08120.16
Receivables
1,5621,6641,6121,2901,3701,265
Inventory
1,1471,2581,056928.61830.97663.87
Other Current Assets
301.17267.47220.86259.62249.71320.22
Total Current Assets
3,8943,9223,7783,2513,6903,585
Property, Plant & Equipment
2,8052,7012,1441,7521,6011,643
Long-Term Investments
643.63693.04691.26717.04696.68640.12
Goodwill
2,7372,7372,7372,7372,7382,738
Other Intangible Assets
1,5961,6681,8261,683751.37658.21
Long-Term Accounts Receivable
----2.16-
Long-Term Deferred Tax Assets
267.97258.22245.21257.81291.47244.38
Long-Term Deferred Charges
714.91730.22773.65964.142,5922,474
Other Long-Term Assets
229.24135.1490.04137.51181.38182.71
Total Assets
12,88812,84512,28611,50012,54412,165

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Accounts Payable
873.62873.39609.12431.36288.4350.86
Accrued Expenses
336.25387.04393.79387.69360.56219.84
Short-Term Debt
1,1891,2041,058609.05673.961,020
Current Portion of Long-Term Debt
283.98248.98544.67489.77554.03419.27
Current Portion of Leases
9.5312.0714.2217.617.9514.54
Current Income Taxes Payable
37.233.7829.2119.1429.5424.19
Current Unearned Revenue
169.57124.89113.63133.23203.2694.82
Other Current Liabilities
120.81149.19224.7699.5371.69158.53
Total Current Liabilities
3,0203,0332,9872,1872,1992,302
Long-Term Debt
954.08858.9627.16812.04850.17730.51
Long-Term Leases
31.4138.9350.5666.7380.6989.8
Long-Term Unearned Revenue
128.99133.87121.21102.16107.29104.12
Long-Term Deferred Tax Liabilities
40.0342.1146.5154.52140.9148.28
Other Long-Term Liabilities
27.1227.1626.4921.8618.9416.02
Total Liabilities
4,2014,1343,8593,2453,3973,391

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Common Stock
1,0371,0371,0371,0461,0461,054
Additional Paid-In Capital
2,8472,8472,8482,9932,9933,048
Retained Earnings
4,9824,8994,6184,3544,9054,712
Treasury Stock
----159-121.01-186.72
Comprehensive Income & Other
-18.9251.7918.9641.31-11.36-92.36
Total Common Equity
8,8478,8358,5228,2768,8128,535
Minority Interest
-160.71-123.55-95.07-20.73334.75239.38
Shareholders' Equity
8,6878,7118,4278,2559,1478,775
Total Liabilities & Equity
12,88812,84512,28611,50012,54412,165

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Total Debt
2,4682,3632,2941,9952,1772,274
Net Cash (Debt)
-1,583-1,630-1,405-1,222-937.51-937.76
Net Cash Growth
------
Net Cash Per Share
-1.30-1.34-1.16-1.00-0.74-0.77
Filing Date Shares Outstanding
1,0371,0371,2161,2161,2191,207
Total Common Shares Outstanding
1,0371,0371,2161,2161,2191,207
Working Capital
874.51888.84791.211,0641,4911,284
Book Value Per Share
8.538.527.016.807.237.07
Tangible Book Value
4,5144,4293,9583,8555,3235,139
Tangible Book Value Per Share
4.354.273.253.174.374.26
Buildings
1,5471,382985.62973.8914.2931.78
Machinery
1,5991,5761,4581,4431,3571,232
Construction In Progress
876.86903.32807.15313.31175.8257.46